24.05.2025 • NewsBrenntagChristian KohlpaintnerPeople

Jens Birgersson Becomes New Brenntag CEO

Jens Birgersson will succeed Christian Kohlpaintner as Chief Executive Officer of Brenntag with effect from September 1, 2025.

Jens Birgersson will become the new CEO of Brenntag with effect from September...
Jens Birgersson will become the new CEO of Brenntag with effect from September 1, 2025.
© Brenntag

With effect from September 1, 2025, Jens Birgersson will become the new CEO of Brenntag. He succeeds Christian Kohlpaintner, who announced in November 2024 that he would not be renewing his contract after almost six years in office. Birgersson, born in 1967 and a Swedish citizen, has more than 20 years of management experience in listed, international market-leading companies in various industries. He was most recently President and CEO of the Danish Rockwool Group since 2015. Educated in Sweden and the USA, he holds a Master's and Bachelor's degree in physical engineering and economics. He began his career at the ABB Group and worked for more than 20 years in Switzerland, Sweden and South Africa. From 2005 to 2008, he was Executive Vice President and Head of the Performance Minerals & Pigments business unit of Imerys, Belgium.

Company

Logo:

Brenntag SE

Messeallee 11
45131 Essen
Netherlands

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read